Effect of iron content on the tolerability of prenatal multivitamins in pregnancy.
BACKGROUND
Gastrointestinal irritability can deter pregnant women from starting or continuing prenatal multivitamin supplementation. In a previous study, suboptimal tolerability was observed among pregnant women taking a large tablet (18 mm x 8 mm x 8 mm) multivitamin with high elemental iron content (60 mg as ferrous fumarate). The objective of the present study was to compare rates of adherence and reported adverse events among pregnant women who were randomized to commence supplementation with a small-tablet prenatal multivitamin, containing either low or high iron content.


METHODS
Pregnant women who called the Motherisk Program (Hospital for Sick Children, Toronto) and had not started taking or had discontinued any multivitamin due to adverse events were included in this prospective, randomized, open-label, 2-arm study. Women were randomized to take a small-size (16 mm x 9 mm x 4 mm), low elemental iron content (35 mg as ferrous fumarate) multivitamin ('35 mg' group); or a small-size (5 mm radius, 5 mm thickness), high elemental iron content (60 mg as ferrous sulphate) multivitamin ('60 mg' group). Follow-up interviews documented pill intake and adverse events. Rates of adherence and adverse events were compared between groups using chi-squared tests and Kaplan-Meier survival curves.


RESULTS
Of 167 randomized women, 92 in the '35 mg' group and 75 in the '60 mg' group were included in the analysis. Despite ideal conditions and regular follow-ups, mean adherence based on pill intake recall, in both groups was approximately 50%. No statistically significant difference was detected in proportions of women who actually started taking either multivitamin. Among those who started, no difference was detected in rates of adherence or reported adverse events.


CONCLUSIONS
The present results suggest that iron content is not a major determinant of adherence to prenatal multivitamins. Combined with our previous study, tablet size may be the more definitive factor affecting adherence.
Nguyen
Patricia
P
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. patricia.nguyen@utoronto.ca
Nava-Ocampo
Alejandro
A
Levy
Amalia
A
O'Connor
Deborah L
DL
Einarson
Tom R
TR
Taddio
Anna
A
Koren
Gideon
G
D000284:Administration, Oral; D000328:Adult; D019587:Dietary Supplements / Q000009:adverse effects*; D005260:Female; D005296:Ferrous Compounds / Q000009:adverse effects; D005767:Gastrointestinal Diseases / Q000209:etiology*; D006801:Humans; D019266:Iron, Dietary / Q000008:administration & dosage / Q000009:adverse effects*; D010349:Patient Compliance; D011247:Pregnancy; D011295:Prenatal Care / Q000592:standards*; D011446:Prospective Studies; D013607:Tablets / Q000145:classification; D014815:Vitamins / Q000008:administration & dosage / Q000009:adverse effects*
D005296:Ferrous Compounds; D019266:Iron, Dietary; D013607:Tablets; D014815:Vitamins; C020748:ferrous sulfate